Micro-X Wins Additional DHS Funding for Advanced Airport Screening Technology.
Micro-X Limited (ASX: MX1) has secured an additional AU$1.3 million contract extension from the U.S. Department of Homeland Security to continue advancing its passenger self-screening checkpoint technology. The funding will mainly support ongoing testing activities and the enhancement of machine learning algorithms designed to improve threat detection performance. The program has now been extended through September 2026, highlighting the continued support from U.S. authorities for the project.
The company is currently producing more checkpoint units to assist with future testing and development stages. Management stated that the latest extension strengthens the collaboration with DHS and moves the technology closer to real-world airport trials. Micro-X’s broader partnership with DHS and the Transportation Security Administration continues to represent a significant long-term opportunity for the company. Micro-X remains focused on developing compact and advanced X-ray imaging systems for both healthcare and security applications worldwide.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Micro-X Wins Additional DHS Funding for Advanced Airport Screening Technology.
Micro-X Limited (ASX: MX1) has secured an additional AU$1.3 million contract extension from the U.S. Department of Homeland Security to continue advancing its passenger self-screening checkpoint technology. The funding will mainly support ongoing testing activities and the enhancement of machine learning algorithms designed to improve threat detection performance. The program has now been extended through September 2026, highlighting the continued support from U.S. authorities for the project.
The company is currently producing more checkpoint units to assist with future testing and development stages. Management stated that the latest extension strengthens the collaboration with DHS and moves the technology closer to real-world airport trials. Micro-X’s broader partnership with DHS and the Transportation Security Administration continues to represent a significant long-term opportunity for the company. Micro-X remains focused on developing compact and advanced X-ray imaging systems for both healthcare and security applications worldwide.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au